Show simple item record

Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital.

dc.contributor.author Anstrom, Kevin J
dc.contributor.author Buggey, J
dc.contributor.author DeVore, Adam David
dc.contributor.author Eisenstein, EL
dc.contributor.author Ersbøll, MK
dc.contributor.author Fiuzat, M
dc.contributor.author Mentz, Robert John
dc.contributor.author O'Connor, CM
dc.contributor.author Schulte, PJ
dc.contributor.author Velazquez, Eric J
dc.coverage.spatial United States
dc.date.accessioned 2015-12-03T21:27:38Z
dc.date.issued 2015-05
dc.identifier http://www.ncbi.nlm.nih.gov/pubmed/25945862
dc.identifier 00005344-201505000-00006
dc.identifier.uri http://hdl.handle.net/10161/11073
dc.description.abstract Furosemide has historically been the primary loop diuretic in heart failure patients despite data suggesting potential advantages with torsemide. We used the Duke Echocardiography Lab Database to investigate patients admitted with heart failure to Duke Hospital from 2000 to 2010 who were discharged on either torsemide or furosemide. We described baseline characteristics based on discharge diuretic and assessed the relationship with all-cause mortality through 5 years. Of 4580 patients, 86% (n = 3955) received furosemide and 14% (n = 625) received torsemide. Patients receiving torsemide were more likely to be female and had more comorbidities compared with furosemide-treated patients. Survival was worse in torsemide-treated patients [5-year Kaplan-Meier estimated survival of 41.4% (95% CI: 36.7-46.0) vs. 51.5% (95% CI: 49.8-53.1)]. After risk adjustment, torsemide use was no longer associated with increased mortality (hazard ratio 1.16; 95% CI: 0.98-1.38; P = 0.0864). Prospective trials are needed to investigate the effect of torsemide versus furosemide because of the potential for residual confounding.
dc.language eng
dc.relation.ispartof J Cardiovasc Pharmacol
dc.relation.isversionof 10.1097/FJC.0000000000000212
dc.subject Academic Medical Centers
dc.subject Aged
dc.subject Comorbidity
dc.subject Databases, Factual
dc.subject Female
dc.subject Furosemide
dc.subject Heart Failure
dc.subject Humans
dc.subject Kaplan-Meier Estimate
dc.subject Male
dc.subject Middle Aged
dc.subject North Carolina
dc.subject Retrospective Studies
dc.subject Risk Factors
dc.subject Sex Factors
dc.subject Sodium Potassium Chloride Symporter Inhibitors
dc.subject Sulfonamides
dc.subject Tertiary Care Centers
dc.subject Treatment Outcome
dc.subject Ultrasonography
dc.title Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital.
dc.type Journal article
pubs.author-url http://www.ncbi.nlm.nih.gov/pubmed/25945862
pubs.begin-page 438
pubs.end-page 443
pubs.issue 5
pubs.organisational-group Basic Science Departments
pubs.organisational-group Biostatistics & Bioinformatics
pubs.organisational-group Clinical Science Departments
pubs.organisational-group Community and Family Medicine
pubs.organisational-group Duke
pubs.organisational-group Duke Clinical Research Institute
pubs.organisational-group Global Health Institute
pubs.organisational-group Institutes and Centers
pubs.organisational-group Institutes and Provost's Academic Units
pubs.organisational-group Medicine
pubs.organisational-group Medicine, Cardiology
pubs.organisational-group Medicine, Clinical Pharmacology
pubs.organisational-group School of Medicine
pubs.organisational-group University Institutes and Centers
pubs.publication-status Published
pubs.volume 65
dc.identifier.eissn 1533-4023


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record